CD4 and neoplasm: A relationship between absolute lymphocyte count and clinical benefit with ipilimumab has been reported, as well as increased expression of inducible costimulator by CD4+ T cells in peripheral blood and tumor tissue resulting in an increase in the ratio of effector to regulatory T cells after ipilimumab treatment.35,36